Details:
The proceeds will enable HEPHAISTOS to prepare for the clinical phases, with the goal of advancing its lead candidate, ONCO-Boost, into clinical development for the treatment of solid tumors with high unmet medical needs, in particular sarcoma.
Lead Product(s): ONCO-Boost
Therapeutic Area: Oncology Product Name: ONCO-Boost
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Xista Science Ventures
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Financing January 23, 2024
Details:
TG6050 is an oncolytic virus developed with Transgene’s Invir.IO™ platform for intravenous administration. TG6050 has been engineered to encode human IL-12, a cytokine that triggers a powerful antitumor immune response and a full length antiCTLA4 antibody.
Lead Product(s): TG6050
Therapeutic Area: Oncology Product Name: TG6050
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.
Lead Product(s): HLA-G/CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CTMC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
IVS-3001 is an HLA-G-targeting chimeric antigen receptor (CAR) T cell therapy. HLA-G is not only an immune checkpoint but also a tumor-specific antigen. IVS-3001 preclinical studies have generated adequate data to support efficacy and safety of the CAR-T therapy.
Lead Product(s): HLA-G/CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CTMA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
TG4001 is a therapeutic cancer vaccine candidate using an attenuated and modified poxvirus (MVA) as a vector expressing the HPV16 E6 and E7 proteins (rendered non-oncogenic) interleukin-2.
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Company will use funds to develop its lead candidate RCT001 (Metastatic Uveal Melanoma) until IND/CTA readiness in 2023, and to expand portfolio of assets with the nomination of a second clinical candidate against Neovascular Glaucoma associated to Uveal melanoma.
Lead Product(s): RCT001
Therapeutic Area: Oncology Product Name: RCT001
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: 3B Future Health Fund II
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 22, 2022
Details:
UCART20x22 is also our first product candidate with fully integrated in-house development, showcasing our transformation into an end-to-end cell and gene therapy company, from discovery, process development, and GMP manufacturing to clinical development.
Lead Product(s): UCART20x22
Therapeutic Area: Oncology Product Name: UCART20x22
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
BVX-0918A, BioVaxys’s cancer vaccines are created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.
Lead Product(s): BVX-0918
Therapeutic Area: Oncology Product Name: BVX-0918
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
AB8939 is a novel microtubule destabilizing agent or synthesized tubulin inhibitor that can circumvent two of the major resistance mechanisms in acute myeloid leukemia (AML), namely P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated resistance.
Lead Product(s): AB8939
Therapeutic Area: Oncology Product Name: AB8939
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
Masitinib is orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity through inhibiting limited number of kinases, can be developed in oncology, inflammatory diseases, and certain diseases of central nervous system.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Oncology Product Name: AB20006
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021